Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes Therapy"
DOI: 10.1007/s13300-019-00709-9
Abstract: The ADA-EASD consensus report recommends using glucagon-like peptide-1 receptor agonists (GLP-1RAs) as the first injectable therapy prior to basal insulin in most patients with type 2 diabetes (T2D) not at glycemic goals after oral anti-hyperglycemia… read more here.
Keywords: patients type; analysis; type diabetes; weekly dulaglutide ... See more keywords
Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes Therapy"
DOI: 10.1007/s13300-019-00726-8
Abstract: Introduction Although global studies have investigated the combination of dulaglutide with insulin in patients with type 2 diabetes mellitus (T2DM), differences in lean body mass and dulaglutide dosing can complicate the extrapolation of global study… read more here.
Keywords: placebo; insulin; insulin therapy; weekly dulaglutide ... See more keywords
Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes Therapy"
DOI: 10.1007/s13300-021-01139-2
Abstract: In the randomized, open-label, parallel-arm, active-controlled phase III AWARD-CHN2 trial, once-weekly dulaglutide plus concomitant oral antihyperglycemic medications (OAMs) improved HbA1c over 26 weeks compared with once-daily insulin glargine in patients with type 2 diabetes mellitus… read more here.
Keywords: dulaglutide chinese; analysis; chinese patients; weekly dulaglutide ... See more keywords
Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"
DOI: 10.2147/dmso.s134960
Abstract: Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, which has been on the market in the USA since 2014. Dulaglutide has performed well in head-to-head studies against metformin, glargine, and sitagliptin, where its A1c lowering… read more here.
Keywords: profile weekly; efficacy safety; safety profile; dulaglutide ... See more keywords
Treatment Effects of Once-Weekly Dulaglutide vs. Insulin Glargine in Patients with Different Baseline Glycemic Patterns (Based on High/Low Fasting or High/Low Postprandial Glucose)—A Post-Hoc Analysis of the AWARD-2 Clinical Trial
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1007-p
Abstract: The effects of DU 1.5 mg and Glar were compared in patients with T2D at 52 weeks from the AWARD-2 study with prevalent elevations in fasting glucose (FG), postprandial glucose (PPG), or both FG and… read more here.
Keywords: effects weekly; high low; postprandial glucose; weekly dulaglutide ... See more keywords